MERSANA: This phase I/II trial is evaluating the safety and clinical activity of a new intravenous cancer treatment for people with high grade serous ovarian cancer or non-small cell lung cancerA Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b

Exclusion

• Major surgery within 28 days of starting study treatment; -or- systemic anti-cancer therapy within the lesser of 28 days or 5 half-lives of the prior therapy before starting study treatment -or- recent radiation therapy with unresolved toxicity.
• Brain metastases that are: untreated, progressive, have required any type of major treatment, e.g., whole-brain radiation treatment, adjuvant chemotherapy, gamma knife, to control symptoms from brain metastases within 30 days of the first study treatment. Or any history of leptomeningeal metastasis.
• Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.
• No prior history of liver disease such as liver cirrhosis, hepatic fibrosis
• Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could interfere with per-protocol evaluations.
• Severe dyspnea at rest due to complications of advanced malignancy, or requiring supplementary oxygen therapy.
• Currently active pneumonitis or interstitial lung disease.
• Pregnant or nursing women.
• History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.
• Participation in the DES component of the study.
• Prior use of mirvetuximab soravtansine or another ADC containing an auristatin or maytansinoid payload.